CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/15/2019
Start Date:July 13, 2017
End Date:December 15, 2019
Contact:Anton F Ehrhadt, PhD
Email:AEhrhadt@mitrabiotech.com
Phone:339 999 2340

Use our guide to learn which trials are right for you!

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice

The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and
different assay developed to test the sensitivity of different cancer types to physician
selected therapies (both drugs and/or drug combinations) indicated for the stage and type of
cancer for treatment. CANscript™ tests how a patients specific tumor reacts to the therapies
being considered by the treating physician. CANscript™ test results have been shown to
closely correspond with actual clinical results, providing physicians with information that
may help him/her develop a more personalized cancer treatment and care plan based on the
patients specific condition. The researchers want to see if CANscript™ test results are
helpful in selecting the treatments prescribed and provided. There will be about 800 people
taking part in this study, across 5 different tumor types. The study is designed to assess
the decision impact of the CANscript™ test results in informing physicians in therapy
selection.

This is an observational data collection study evaluating how physicians utilize therapeutic
sensitivity information ascertained with CANscript, and subsequently describing clinical
outcomes (clinical response and survival) resulting from their therapeutic selection.

Potential patients presenting for study enrollment will provide written informed consent and
will subsequently be screened per inclusion/ exclusion criteria. Once enrolled, a biopsy &
blood draw will be scheduled to obtain material for CANscript testing. Imaging will also be
scheduled if a fresh image (obtained within 14 days of planned treatment initiation) is not
available. Prior to submitting a fresh tissue sample for CANscript, the treating physician
will select any number of therapies being considered for treatment, and will assign a
priority ranking to those therapies (priority #1 through priority #N, with #1 representing
their most preferred therapeutic option for the patient, and #N representing the number of
their least preferred of the appropriate potential therapies). Prioritized therapies can be
either single-agent therapeutics or combination regimens. All ranked therapeutic options must
be available for individual patient at the time of selection. The prioritized list of
preferred therapies will be sent to the testing laboratory (Mitra Biotech, Inc.) at least 2
days before the biopsy and blood draw are performed. Fresh tumor and blood samples will
subsequently be sent to the testing laboratory for receipt within 24 hours of biopsy.

Inclusion Criteria:

1. Male or female patient ≥18 years old

2. ECOG performance status of ≤ 2

3. The patient's tumor must be amenable to a tumor biopsy sampling, so that CANscript can
be performed

4. The patient must have disease that is measurable by standard imaging techniques, per
the RECIST 1.1 (For patients with prior radiation therapy, measurable lesions must be
outside of any prior radiation field[s], unless disease progression has been
documented at that disease site subsequent to radiation)

5. Histologically- or cytologically-confirmed:

A Locally advanced or metastatic HNSCC; B Locally advanced or metastatic TNBC; C
Locally advanced or metastatic Stage 3b or 4 NSCLC after failure of appropriate 1st
line therapy (i) Patients with EGFR or ALK mutations must have received previous
appropriate therapy; D Locally advanced or metastatic epithelial ovarian, fallopian
tube, or primary peritoneal carcinoma, after failure of 1st line platinum-based
chemotherapy (i) Recurrent or persistent stage 3 or 4 disease requiring relapse
histologic documentation; E Stage IV metastatic CRC

6. Patient has signed informed consent prior to initiation of any study-specific
procedures

Exclusion Criteria:

1. The patient has persistent clinically significant toxicities (Grade ≥2) from previous
anticancer therapy (excluding chronic Grade 2 chemotherapy-related neuropathy which is
permitted, and excluding Grade 2-3 laboratory abnormalities if they are not associated
with symptoms, are not considered clinically significant by the Investigator, and can
be managed with available medical therapies).

2. The patient has received treatment with chemotherapy, external-beam radiation, or
other systemic anticancer therapy within 14 days prior to study entry (42 days for
prior nitrosourea or mitomycin-C). (Patients could have received supportive care
therapeutics as appropriate).

3. The patient has an additional active malignancy that may confound the assessment of
the study endpoints. Patients with a past cancer history (active malignancy within 2
years prior to study entry) with substantial potential for recurrence must be
discussed with the Sponsor before study entry. Patients with the following concomitant
neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ
(including transitional cell carcinoma, cervical intraepithelial neoplasia),
organ-confined prostate cancer with no evidence of progressive disease.

4. The patient has clinically significant cardiovascular disease (e.g., uncontrolled or
any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled
angina, history of myocardial infarction, unstable angina or stroke within 6 months
prior to study entry, uncontrolled hypertension or clinically significant arrhythmias
not controlled by medication).

5. The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic
obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the
Investigator would put the patient at significant risk for pulmonary complications
during the study.

6. The patient has known active or suspected brain or leptomeningeal metastases. (Central
nervous system [CNS] imaging is not required prior to study entry unless there is a
clinical suspicion of CNS involvement). Patients with stable, treated brain metastases
are eligible provided there is no evidence of CNS disease growth on imaging for at
least 6 weeks following radiation therapy or other loco-regional ablative therapy to
the CNS.

7. The patient is receiving immunosuppressive therapy for prophylaxis following a prior
organ transplant (solid organ or allogeneic stem cell). Corticosteroid therapy is
permitted.

8. The patient has uncontrolled intercurrent illness including, but not limited to,
uncontrolled infection, disseminated intravascular coagulation, or psychiatric
illness/social situations that would limit compliance with study requirements.

9. The patient is pregnant or breast-feeding. The patient has known positive status for
human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
We found this trial at
32
sites
Gilbert, Arizona 85234
Principal Investigator: Madappa Kundranda, MD
Phone: 480-256-5423
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
6405 N Federal Hwy # 300
Fort Lauderdale, Florida 33308
Principal Investigator: Luis Barreras, MD
Phone: 954-771-0692
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Zdenka E Segota, MD
Phone: 954-267-7748
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Saketh Guntupalli, MD
Phone: 303-724-8467
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Austin, Texas 78759
Principal Investigator: Rachel Brightwell, MD
Phone: 512-354-6391
?
mi
from
Austin, TX
Click here to add this to my saved trials
Boca Raton, Florida 33486
Principal Investigator: Edgardo S Santos Castillero, MD
Phone: 561-955-4800
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Edinburg, Texas 78539
Principal Investigator: Carlos Garcia-Cantu, MD
Phone: 956-362-2384
?
mi
from
Edinburg, TX
Click here to add this to my saved trials
Fairhaven, Massachusetts 02719
Principal Investigator: Sonia Seng, MD
Phone: 508-973-3152
?
mi
from
Fairhaven, MA
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
Principal Investigator: Jeffery Margolis, MD
Phone: 248-747-4383
?
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
301 University Boulevard
Galveston, Texas 77550
Principal Investigator: Maurice Willis, MD
Phone: 409-772-0575
?
mi
from
Galveston, TX
Click here to add this to my saved trials
Grosse Pointe Woods, Michigan 48236
Principal Investigator: Carrie Dul, MD
Phone: 313-647-3013
?
mi
from
Grosse Pointe Woods, MI
Click here to add this to my saved trials
Houston, Texas 77203
Principal Investigator: Julio Peguero, MD
Phone: 713-600-0913
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Brandon G Smaglo, MD
?
mi
from
Houston, TX
Click here to add this to my saved trials
6565 Fannin Street
Houston, Texas 77030
Principal Investigator: Aapama Kamat, MD
Phone: 713-441-6616
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Joseph III Lucci, MD
Phone: 713-500-6919
?
mi
from
Houston, TX
Click here to add this to my saved trials
Joliet, Illinois 60435
Principal Investigator: Nafisa Burhani, MD
Phone: 815-730-3098
?
mi
from
Joliet, IL
Click here to add this to my saved trials
McAllen, Texas 78577
Principal Investigator: Eugenio G Galindo, MD
Phone: 956-517-4690
?
mi
from
McAllen, TX
Click here to add this to my saved trials
1475 NW 12th Ave
Miami, Florida 33136
(305) 243-1000
Principal Investigator: Mohammad Jahanzeb, MD
Phone: 305-243-0864
University of Miami, Sylvester Comprehensive Cancer Center Sylvester Comprehensive Cancer Center integrates all cancer-related activities...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miramar, Florida 33027
Principal Investigator: Emery Salom, MD
Phone: 954-602-9723
?
mi
from
Miramar, FL
Click here to add this to my saved trials
Munster, Indiana 46321
Principal Investigator: Neel Shah, MD
Phone: 219-836-3349
?
mi
from
Munster, IN
Click here to add this to my saved trials
Naperville, Illinois 60540
Principal Investigator: George Salti, MD
Phone: 630-646-6072
?
mi
from
Naperville, IL
Click here to add this to my saved trials
Nashville, Tennessee 37205
Principal Investigator: Michael Stany, MD
Phone: 615-222-4356
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Marc R Matrana, MD
Phone: 504-703-2654
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Norwich, Connecticut 06360
Principal Investigator: Dennis Slater, MD
Phone: 860-886-8362
?
mi
from
Norwich, CT
Click here to add this to my saved trials
Orlando, Florida 32804
Principal Investigator: Nathalie Mckenzie, MD
Phone: 407-303-2800
?
mi
from
Orlando, FL
Click here to add this to my saved trials
8100 Southwest 10th Street
Plantation, Florida 33324
Phone: 954-582-1850
?
mi
from
Plantation, FL
Click here to add this to my saved trials
Rochester, New York 14642
Principal Investigator: Richard G Moore, MD
Phone: 585-275-7763
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Saint Louis, Missouri 63141
Principal Investigator: Kevin Easley, MD
Phone: 314-251-7077
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Sault Sainte-Marie, Michigan 49783
Principal Investigator: Ahmad Maksoud, MD
Phone: 906-253-2685
?
mi
from
Sault Sainte-Marie, MI
Click here to add this to my saved trials
Savannah, Georgia 31404
Principal Investigator: James Burke, MD
Phone: 912-350-7878
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Tallahassee, Florida 32308
Principal Investigator: Karen Russell, MD
Phone: 850-431-0673
?
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Worcester, Massachusetts 01655
Principal Investigator: William Walsh, MD
Phone: 774-445-4457
?
mi
from
Worcester, MA
Click here to add this to my saved trials